Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Paraganglioma 6Meningioma 6Pheochromocytoma 5Neuroendocrine Tumors 4Neuroblastoma 3Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Hypertension 1Gastro-enteropancreatic neuroendocrine tumor 1Esthesioneuroblastoma, Olfactory 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Medullary 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Nivolumab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1lutetium Lu 177 dotatate 1entinostat 1Trastuzumab 1Specimen Handling 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Indinavir 1Immunotherapy 1Gefitinib 1Drug Therapy 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parathyroid Neoplasms × lutetium Lu 177 dotatate × CNS × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡